304 related articles for article (PubMed ID: 22921697)
1. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
[TBL] [Abstract][Full Text] [Related]
2. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
[TBL] [Abstract][Full Text] [Related]
3. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
4. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
[TBL] [Abstract][Full Text] [Related]
5. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
[TBL] [Abstract][Full Text] [Related]
7. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
[TBL] [Abstract][Full Text] [Related]
8. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
9. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
10. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
Baraban E; Erak E; Fatima A; Akbari A; Zhao J; Fletcher SA; Bhanji Y; de la Calle CM; Mamawala M; Landis P; Macura KJ; Pavlovich CP; Epstein JI
J Urol; 2023 Jul; 210(1):99-107. PubMed ID: 37042826
[TBL] [Abstract][Full Text] [Related]
11. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
12. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
13. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
14. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
16. Ability of sextant biopsies to predict radical prostatectomy stage.
Wills ML; Sauvageot J; Partin AW; Gurganus R; Epstein JI
Urology; 1998 May; 51(5):759-64. PubMed ID: 9610589
[TBL] [Abstract][Full Text] [Related]
17. Minute focus of prostate cancer on needle biopsy: correlation with radical prostatectomy specimen.
Montanari E; Del Nero A; Gazzano G; Mangiarotti B; Bernardini P; Longo F; Cordima G; Itri E
Arch Ital Urol Androl; 2009 Mar; 81(1):9-12. PubMed ID: 19499751
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
[TBL] [Abstract][Full Text] [Related]
19. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
20. Optimizing patient selection for prostate monotherapy.
Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
